| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | -0.014 | 0.9 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |